The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

PURPOSE: A stability improved sulglycotide a multi-layer tablet and a manufacturing method thereof are provided to have better damaged stomach protection effects than respectively administrating the sulglycotide and a H2 receptor antagonist. CONSTITUTION: A pharmaceutical composition for treating or preventing gastrointestinal disorder comprises sulglycotide and H2 receptor antagonist as active ingredients. The H2 receptor antagonist is nizatidine ranitidine famotidine cimetidine or lafutidine. ...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

PROBLEM TO BE SOLVED: To provide an oral liquid medicine including nizatidine whose bitterness is masked.SOLUTION: This oral liquid medicine includes nizatidine as an active ingredient and at least one kind of flavor selected from flavors based on crude medicines and at least one kind of sweetener selected from the group consisting of sugars (excluding reducing sugars) sugar alcohols saccharin and its salt.COPYRIGHT: (C)2003JPO

The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition, which is intended for the treatment of pathologies linked to gastric hyperacidity, comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine, ranitidine, famotidine and nizatidine. The invention is particularly suitable for the treatment of duodenal and gastric ulcers and the symptoms of, and lesions caused by, gastroesophagea...

The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition which is intended for the treatment of pathologies linked to gastric hyperacidity comprises a combination of tenatoprazole and one or more histamine H2-receptor antagonists preferably selected from cimetidine ranitidine famotidine and nizatidine. The invention is particularly suitable for the treatment of duodenal and gastric ulcers and the symptoms of and lesions caused by gastroesophageal refl...